UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 001-40407 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 81-2744449 (State or other jurisdiction ...

Exhibit 99.1 Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results BRISBANE, Calif., February 26, 2026 – Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical- stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the full year ended December 31, 2025. "In 2025, Vera Therapeutics delivered on several key milestones as ...

Positive Phase 3 data from ORIGIN 3 study of atacicept in IgA nephropathy (IgAN) presented at American Society of Nephrology (ASN) Kidney Week and published in the New England Journal of MedicineU.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for atacicept with Prescription Drug User Fee Act (PDUFA) date of July 7, 2026; potential commercial launch of atacicept expected in mid-2026Strong balance sheet bolstered by equity and debt financings in 2025 expe ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Core Insights - Generative AI is viewed as a transformative technology by Amazon's CEO Andy Jassy, indicating its potential to significantly enhance customer experiences across the company [1] - Elon Musk predicts that by 2040, humanoid robots could create a market worth $250 trillion, representing a major shift in the global economy driven by AI innovation [2][3] - Major firms like PwC and McKinsey acknowledge the potential of AI to unlock multi-trillion-dollar opportunities, reinforcing the optimistic outlook on AI's economic impact [3] Company and Industry Analysis - A breakthrough in AI technology is believed to be redefining work, learning, and creativity, leading to increased interest from hedge funds and top investors [4] - There is speculation about an under-owned company that may play a crucial role in the AI revolution, suggesting that it could be a significant investment opportunity [4][6] - Prominent figures in technology and finance, including Bill Gates and Warren Buffett, recognize AI as a major technological advancement with the potential for substantial social benefits [8]

Group 1 - Vera Therapeutics (NASDAQ:VERA) is identified as one of the 17 biotechnology stocks with more than 50% upside potential, with a price target of $96 set by JPMorgan, indicating an upside of over 127% from current levels [1][3] - Cantor Fitzgerald also maintains an Overweight rating on Vera Therapeutics, with a target price of $100, suggesting nearly 137% upside potential, highlighting favorable conditions for the approval of atacicept for treating IgA-related kidney disorder [4] - The company is a late-stage clinical biotechnology firm focused on immunological conditions, developing treatments for serious diseases, including immunoglobulin A nephropathy and MAU868, a monoclonal antibody for BK viremia infections in transplant patients [5] Group 2 - Anupam Rama from JPMorgan anticipates that as competitors' clinical data becomes available, Vera Therapeutics' stock price could rise towards a more appropriate risk-adjusted valuation [3] - The company is positioned for a successful market entry once it obtains regulatory approvals, indicating strong opportunities for growth [4]

Core Thesis - Vera Therapeutics, Inc. is positioned as a promising investment opportunity due to its focus on atacicept, a biologic therapy targeting IgA nephropathy, a significant cause of chronic kidney disease [2][4]. Company Overview - Vera Therapeutics is a clinical-stage biotechnology company dedicated to developing therapies for autoimmune diseases, primarily through its lead asset, atacicept [2]. - Atacicept aims to address the root cause of IgA nephropathy by blocking the production of pathogenic IgA antibodies, moving beyond traditional symptom management approaches [3]. Market Opportunity - The total addressable market for IgA nephropathy is estimated at $10 billion in the U.S., which could double when including Europe and Japan [4]. - Approximately 100,000 patients in the U.S. are affected by IgA nephropathy, with around half requiring advanced treatment options [4]. Revenue Potential - Vera anticipates commercial shipments of atacicept to begin in 2026, with expectations of capturing a 15%–25% market share, leading to peak annual revenues of $1.5–$2.5 billion [4]. - The drug is positioned to become a blockbuster by the end of the decade, supported by strong clinical data [4][5]. Clinical Data and Regulatory Pathway - Recent Phase 3 clinical trial results published in the New England Journal of Medicine indicate that atacicept is both safe and effective, bolstering its commercial prospects [5]. - Vera has submitted a Biologics License Application under the FDA's Accelerated Approval Program, aiming for potential commercialization in mid-2026 [5]. Competitive Landscape - Despite positive developments, Vera's stock has remained stable, likely due to investor caution regarding a competing therapy's regulatory decision [6]. - The large and underserved market for IgA nephropathy suggests that multiple therapies can coexist, potentially validating the market opportunity [6]. Valuation and Investment Appeal - Vera is considered undervalued at approximately 5 times its potential peak revenues, presenting a compelling risk-reward profile with clear upside catalysts [6].

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgent need for energy to support its growth [1][2][3] AI and Energy Demand - AI technologies, particularly large language models like ChatGPT, are extremely energy-intensive, with data centers consuming as much energy as small cities [2] - The increasing demand for AI is straining global power grids, leading to rising electricity prices and a need for utilities to expand capacity [2] Investment Opportunity - A specific company, largely overlooked by AI investors, is positioned to benefit from the anticipated surge in energy demand due to AI [3][6] - This company owns critical energy infrastructure assets and is involved in the U.S. LNG exportation sector, which is expected to grow under the current administration's energy policies [7][8] Financial Position - The company is noted for being debt-free and holding a significant cash reserve, amounting to nearly one-third of its market capitalization [8] - It also has a substantial equity stake in another AI-related company, providing investors with indirect exposure to multiple growth opportunities without high premiums [9] Market Perception - Wall Street is beginning to recognize this company as a valuable investment, especially as it operates without the high valuations typical of many energy and utility firms [8][10] - The company is trading at less than 7 times earnings, making it an attractive option for investors looking for undervalued stocks in the AI and energy sectors [10] Future Outlook - The ongoing AI revolution is expected to disrupt traditional industries, with companies that adapt to AI technologies likely to thrive [11][12] - The influx of talent into the AI sector is anticipated to drive continuous innovation and advancements, reinforcing the importance of investing in this field [12][13] Strategic Context - The company is strategically positioned to capitalize on the AI infrastructure supercycle, the onshoring boom due to tariffs, and the surge in U.S. LNG exports [14]

Core Insights - Vera Therapeutics has appointed Matt Skelton as Chief Commercial Officer to lead the commercial launch of atacicept for IgA nephropathy [1][2] - Atacicept is a promising investigational treatment that targets B-cell activation and has shown significant clinical efficacy in trials [3][4][6] Company Overview - Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases [10] - The company's lead product candidate, atacicept, is designed to block B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which are involved in autoimmune diseases [10] Leadership Appointment - Matt Skelton brings extensive experience in global commercialization, having previously scaled Seagen's commercial organization from one product to four approved products [2][10] - His leadership is expected to be critical in transitioning Vera Therapeutics into a commercial-stage company [2] Atacicept Clinical Program - The ORIGIN Phase 2b clinical trial of atacicept met its primary and key secondary endpoints, showing significant reductions in proteinuria and stabilization of eGFR [4] - The ongoing ORIGIN 3 Phase 3 trial has also met its primary endpoint with a statistically significant reduction in proteinuria at week 36 [5] Regulatory Status - Atacicept has received Breakthrough Therapy Designation from the FDA for IgA nephropathy, indicating its potential to significantly improve treatment outcomes [6] - The Biologics License Application (BLA) for atacicept has received Priority Review designation, with a target action date set for July 7, 2026 [7] Future Studies - The ORIGIN Extend study allows participants to access atacicept until its commercial availability and collects long-term safety and efficacy data [8] - Atacicept is also being evaluated in other autoimmune kidney diseases, expanding its potential therapeutic applications [8][10]

分组1 - Sherry Paul from Morgan Stanley discusses market volatility, emphasizing it as a normal part of investing and indicating a shift from the 'Magnificent Seven' to 'magnificent thematics' such as AI automation and innovation [1][2] - The MAG7 companies are evolving into diversified holding companies, with traditional sector labels becoming distorted as tech firms venture into new industries [2] - Paul recommends an equal-weight approach for ETF investors to avoid over-concentration in mega-cap stocks and suggests focusing on the remaining 473 stocks in the S&P 500 for investment opportunities [2] 分组2 - Apellis Pharmaceuticals Inc. (NASDAQ:APLS) has an average upside potential of 47.33%, with Bank of America upgrading its rating to Buy, citing undervalued prospects for its drug Empaveli in treating rare kidney diseases [7][8] - Wells Fargo has reduced its price target for Apellis to $26 from $29, reflecting a slower-than-expected commercial ramp for Empaveli, while cutting revenue estimates for 2026-2030 by 20% to 50% [9][10] - Vera Therapeutics Inc. (NASDAQ:VERA) shows an average upside potential of 55.09%, with Bank of America raising its price target from $48 to $66 due to increased revenue forecasts for its lead drug [11][12] - Goldman Sachs and JPMorgan have also raised their price targets for Vera Therapeutics, reflecting a broader market potential and positive developments in its drug pipeline [12][13]